Investigational A3adenosine receptor targeting agents

Antiretroviral Chemotherapy: New Investigational Agents

As in previous years, the 9th Conference on Retroviruses and Opportunistic Infections provided a forum for a stateof-the-art update in antiretroviral therapy. Highlights included the status of new antiretroviral agents from both existing and new drug classes; presentation of trials in antiretroviral-naive and antiretroviral-experienced persons; updates on strategic approaches to therapy, includ...

Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.

INTRODUCTION Antipsychotic drugs date back to the 1950s and chlorpromazine. Soon after, it was established that blockade of dopamine and, in particular, the D2 receptor was central to this effect. Dopamine continues to represent a critical line of investigation, although much of the work now focuses on its potential in other symptom domains. AREAS COVERED A search was carried out for investig...

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib.

Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge™) is a novel first-in-human, first-in class, orally bio-available Hedgehog pathway signaling inhibitor of the G-protein coupled receptor-like protein smoothened (SMO) which was approved in the United States on January 2012. This signaling pathway is involved in the carcinogenesis of several ...

Activities of available and investigational antifungal agents against rhodotorula species.

Rhodotorula species are emerging pathogens in immunocompromised patients. We report the in vitro activities of eight antifungals against 64 Rhodotorula isolates collected in surveillance programs between 1987 and 2003. Rhodotorula strains are resistant in vitro to fluconazole (MIC at which 50% of the isolates tested are inhibited [MIC(50)], >128 microg/ml) and caspofungin (MIC(50), >8 microg/ml...

Development of rational drug combinations with investigational targeted agents.